• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Portfolio data
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • AGTC
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
      • Kesmalea Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • Neogene Therapeutics
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chair, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

Portfolio data

Browse all portfolio data news

    Latest portfolio data news

    Show news from
    • all companies
    • all Cell therapy companies
    • Autolus
    • Achilles Therapeutics
    • all Gene therapy companies
    • Freeline Therapeutics
    • all Biologics companies
    • Anaveon
    • all Small molecule companies
    21.07.22

    New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

    • Operating News
    • Gene therapy
    • Freeline Therapeutics
    10.07.22

    Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

    • Gene therapy
    • Freeline Therapeutics
    10.06.22

    Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

    11.04.22

    Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

    • Biologics
    • Anaveon
    08.02.22

    Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM

    • Gene therapy
    • Freeline Therapeutics
    13.12.21

    Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

    • Cell therapy
    • Autolus
    Load more

    Sign-up for company news alerts

    Get the latest RNS, company news, share price information and results from Syncona

    • RNS alerts
    • Company alerts

    Syncona Investment Management Limited
    2nd Floor
    8 Bloomsbury Street
    London
    WC1B 3SR
    contact@synconaltd.com

    • About us
    • Our people
    • Portfolio
    • Sustainability
    • News and Insights
    • Investors
    • Contact
    • Copyright © Syncona 2023
    • Accessibility
    • Privacy & cookies
    • Employee privacy notice
    • Third party privacy notice
    • Regulatory publications
    • Modern Slavery Statement

    Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
    Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

    Designed & built by SampsonMay
    • About us
      • About us
      • Who we are
      • Our model
      • Data driven investment process
      • Our purpose, culture and values
      • Our history
    • Our people
      • Our people
      • Board of directors
    • Portfolio
      • Portfolio
      • Portfolio data
      • Cell therapy
        • Overview
        • Autolus
        • Achilles Therapeutics
        • Quell Therapeutics
        • Resolution Therapeutics
        • Clade Therapeutics
      • Gene therapy
        • Overview
        • Freeline Therapeutics
        • AGTC
        • SwanBio Therapeutics
        • Purespring Therapeutics
      • Biologics
        • Overview
        • Anaveon
      • Small molecule
        • Overview
        • OMass Therapeutics
        • Kesmalea Therapeutics
      • Previous investments
        • Overview
        • Gyroscope Therapeutics
        • Blue Earth
        • Nightstar
        • Neogene Therapeutics
        • 14MG
        • Azeria Therapeutics
    • Sustainability
      • Sustainability
      • Message from Chair, SIML
      • Our approach to sustainability reporting
      • Our social impact
      • Responsible investor and partner
        • Overview
        • Responsible investment process
        • A responsible partner
        • Sustainability within the Syncona portfolio
      • Inspiring and empowering our people
      • Responsible and ethical business
        • Overview
        • Environment
        • Syncona TCFD disclosure
      • Syncona’s approach to charity
        • Overview
        • The Syncona Foundation
      • Sustainability policies
    • News and Insights
    • Investors
      • Investors
      • Investment proposition
      • KPIs
      • Results and presentations
      • RNS and inside information
      • Share price centre
      • Governance
        • Overview
        • Our Committees
        • How we communicate with our stakeholders
      • Regulatory publications
      • Financial calendar
      • Analysts and advisers
      • Shareholder information
        • Overview
        • Shareholder documents
      • FAQs
    • Contact
    GBX 149.20
    Change: +4.20 (+2.90%)

    Search